Clinical benefit from palliative chemotherapy in non-small-cell lung cancer extends to the elderly and those with poor prognostic factors
1998

Palliative Chemotherapy Benefits Elderly with Lung Cancer

Sample size: 290 publication Evidence: moderate

Author Information

Author(s): TF Hickish, IE Smith, MER O'Brien, S Ashley, G Middleton

Primary Institution: Royal Marsden NHS Trust

Hypothesis

The study aimed to identify pretreatment characteristics that predict survival, response, and symptom relief in patients with non-small-cell lung cancer (NSCLC).

Conclusion

Older patients with advanced NSCLC can benefit from palliative chemotherapy, experiencing symptom relief despite poor prognostic factors.

Supporting Evidence

  • Older age was positively associated with objective response (P=0.04).
  • 54% of patients at high risk of death had symptom relief from chemotherapy.
  • 30-48% of patients with adverse prognostic factors still experienced symptom relief.

Takeaway

Even older people with lung cancer can feel better with chemotherapy, even if their situation looks bad.

Methodology

The study analyzed 290 patients with advanced NSCLC treated with cisplatin-based chemotherapy, collecting data on 37 pretreatment variables and using univariate and multivariate analyses.

Limitations

The study may not account for all factors influencing symptom relief, as supportive care could also affect outcomes.

Participant Demographics

The age range was 28-78 years, with 44% of patients over 60 years; 65% were male.

Statistical Information

P-Value

0.04

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication